Hyperforin, a new lead compound against the progression of cancer and leukemia?

被引:60
作者
Quiney, C.
Billard, C.
Salanoubat, C.
Fourneron, J. D.
Kolb, J. P.
机构
[1] Ctr Rech Biomed Cordeliers, INSERM, UMRS 76, F-75270 Paris 06, France
[2] Hop Hotel Dieu, Dept Hematol & Oncol Med, F-75181 Paris, France
[3] Fac Pharm Marseille, Lab Pharm Galen & Ind, Marseille, France
关键词
hyperforin; St John's wort; cancer; apoptosis; angiogenesis;
D O I
10.1038/sj.leu.2404301
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Extracts of the plant St John's wort, Hyperforin perforatum L., have been used for centuries in traditional medicine, notably for the treatment of depression. One of their main lipophilic components, a natural prenylated phloroglucinol termed hyperforin (HF), has been identified as the major molecule responsible for the antidepressant effects of this plant. Within the last few years, a number of studies have demonstrated that HF displays, in addition, several other biological properties of potential pharmacological interest. They include an antibacterial capacity and inhibitory effects on inflammatory mediators. It is worth noting that HF also promotes apoptosis of various cancer cells from solid tumors and hematological malignancies, including B-cell chronic lymphocytic leukemia. In addition, HF inhibits the capacity of migration and invasion of different tumor cells, as well as exhibiting antiangiogenic effects. Altogether, these properties qualify HF as a lead structure for the development of new therapeutic molecules in the treatment of various diseases, including some malignant tumors.
引用
收藏
页码:1519 / 1525
页数:7
相关论文
共 77 条
[1]   Biosynthesis of hyperforin in Hypericum perforatum [J].
Adam, P ;
Arigoni, D ;
Bacher, A ;
Eisenreich, W .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (21) :4786-4793
[2]   Hypericin in cancer treatment: more light on the way [J].
Agostinis, P ;
Vantieghem, A ;
Merlevede, W ;
de Witte, PAM .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2002, 34 (03) :221-241
[3]   Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase [J].
Albert, D ;
Zündorf, I ;
Dingermann, T ;
Müller, WE ;
Steinhilber, D ;
Werz, O .
BIOCHEMICAL PHARMACOLOGY, 2002, 64 (12) :1767-1775
[4]   Extracts from St John's Wort and their antimicrobial activity [J].
Avato, P ;
Raffo, F ;
Guglielmi, G ;
Vitali, C ;
Rosato, A .
PHYTOTHERAPY RESEARCH, 2004, 18 (03) :230-232
[5]   St John's wort (Hypericum perforatum L.):: a review of its chemistry, pharmacology and clinical properties [J].
Barnes, J ;
Anderson, LA ;
Phillipson, JD .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2001, 53 (05) :583-600
[6]   Oral bioavailability of hyperforin from Hypericum extracts in rats and human volunteers [J].
Biber, A ;
Fischer, H ;
Romer, A ;
Chatterjee, SS .
PHARMACOPSYCHIATRY, 1998, 31 :36-43
[7]   In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs [J].
Butterweck, V ;
Nahrstedt, A ;
Evans, J ;
Hufeisen, S ;
Rauser, L ;
Savage, J ;
Popadak, B ;
Ernsberger, P ;
Roth, BL .
PSYCHOPHARMACOLOGY, 2002, 162 (02) :193-202
[8]  
BYSTROV NS, 1975, TETRAHEDRON LETT, P2791
[9]   Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts [J].
Cervo, L ;
Rozio, M ;
Ekalle-Soppo, CB ;
Guiso, G ;
Morazzoni, P ;
Caccia, S .
PSYCHOPHARMACOLOGY, 2002, 164 (04) :423-428
[10]   Quantitative analysis of the major constituents of St John's wort with HPLC-ESI-MS [J].
Chandrasekera, DH ;
Welham, KJ ;
Ashton, D ;
Middleton, R ;
Heinrich, M .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2005, 57 (12) :1645-1652